Author's Accepted Manuscript

Integrin, alpha9 subunit blockade suppresses collagen-induced arthritis with minimal systemic immunomodulation

Shingo Sugahara, Kaori Hanaoka, Nobuchika Yamamoto



PII:S0014-2999(18)30354-6DOI:https://doi.org/10.1016/j.ejphar.2018.06.021Reference:EJP71851

To appear in: European Journal of Pharmacology

Received date:14 January 2018Revised date:17 June 2018Accepted date:18 June 2018

Cite this article as: Shingo Sugahara, Kaori Hanaoka and Nobuchika Yamamoto, Integrin, alpha9 subunit blockade suppresses collagen-induced arthritis with minimal systemic immunomodulation, *European Journal of Pharmacology*, https://doi.org/10.1016/j.ejphar.2018.06.021

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Integrin, alpha9 subunit blockade suppresses collagen-induced arthritis with minimal systemic

immunomodulation

Shingo Sugahara^{*}, Kaori Hanaoka, Nobuchika Yamamoto

Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, 305-8585, Japan

*Corresponding author. Shingo Sugahara. Tel.: +81-29-829-6252; fax: +81-29-852-2955.

shingo.sugahara@astellas.com

ABSTRACT

Integrin, alpha9 subunit (hereinafter, alpha9) has been identified as a novel putative therapeutic target for rheumatoid arthritis (RA). Support for this target comes from the observations that alpha9 is overexpressed both in the joints of RA patients and in animal models of arthritis. In the experimental models, the increase in alpha9 expression precedes the onset of arthritic symptoms. The current study presents data on the pharmacological profile of an anti-alpha9 antibody in a collagen-induced arthritis (CIA) mouse model. Administration of an alpha9-blocking antibody in CIA mice suppressed the development of arthritis and significantly decreased plasma level of activated fibroblast-like synoviocyte (FLS)-derived biomarkers without reducing the formation of

dmanus

Download English Version:

https://daneshyari.com/en/article/8528994

Download Persian Version:

https://daneshyari.com/article/8528994

Daneshyari.com